Scientific recommendation on classification of advanced therapy medicinal products


Disclaimer: This document is a summary for public release of a scientific recommendation on classification of advanced therapy medicinal products. The original text adopted by the Committee for Advanced Therapies (CAT) has been redacted to delete commercially confidential information. The present scientific recommendation refers exclusively to the case as presented to the European Medicines Agency (EMA) without prejudice to future evaluations by the Agency.

Brief description (or name where available) of the active substance(s)

Autologous dendritic cells loaded with autologous irradiated tumour stem cells.

Brief description of the finished product

Suspension of cells in cryopreservation medium

Proposed indication

Treatment of melanoma

EMA/CAT conclusion

The committee adopted on 17th April 2015 the following scientific recommendation.

On the basis that:

- the product consists of cells that have been subject to substantial manipulation so that biological characteristics, physiological functions or structural properties relevant for the intended clinical use have been altered,

- the product is presented as having properties for, or is administered to human beings with a view to treating a disease through the immunological action of its cells.
The EMA/CAT considers that the Product falls within the definition of a somatic cell therapy medicinal product as provided in Article 2 (1) (a) of Regulation (EC) No 1394/2007